We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Technology to Treat Lumbar Spinal Stenosis

By HospiMedica International staff writers
Posted on 10 Mar 2009
Alphatec Spine (Carlsbad, CA, USA), a medical device company that designs, develops, manufactures, and markets products for the surgical treatment of spine disorders, has announced that it has entered into a license agreement with Helix Point (Shermans Dale, PA, USA) to develop and commercialize two interspinous devices to treat lumbar spinal stenosis (LSS). More...


The Helifix is a non-fusion interspinous device designed to provide relief from the symptoms of LSS by providing flexion in the posterior elements; the Helifuse is similar in design to Helifix, but will be a fusion device that may be combined with percutaneous spinal fixation. Both devices work by preventing extension at the spinal level of interest, thus reducing symptoms. The Helifix device is self-distracting and can be made from a variety of materials including titanium, polyaryletheretherketone (PEEK), or bone, and is designed so that it can be inserted and removed percutaneously. It can be inserted by spine surgeons and interventional radiologists, and the procedure can be performed on an inpatient or outpatient basis. Because of the design and the different materials that can be used, the device could be used for both fusion and nonfusion procedures.

"It is estimated that 37% of surgeries on patients age 65 or older are for spinal stenosis,” said Dirk Kuyper, president and CEO of Alphatec Spine. "Helifix and Helifuse will allow surgeons to treat the older patient with spinal stenosis in a minimally invasive manner. These products complement our growing portfolio of aging spine products.”

"Neural passageways are compromised by aging and exacerbated by extension in patients with spinal stenosis,” said James J. Yue, M.D., a member of Alphatec Spine's scientific advisory board and an associate professor at Yale University (New Haven, CT, USA). "Clinical observations of patients show they experience relief in their symptoms with flexion. So it stands to reason that by preventing extension at the level of interest, symptoms may be reduced or eliminated.”

LSS arises from age-related changes to the facets and the intervertebral disc that can eventually lead to a reduction in the patient's quality of life. More than two million people 65 years and older in the United States were diagnosed with spinal stenosis in 2008. There were more than 145,000 of these procedures performed on LSS patients aged 65 years and older in 2008, and it is estimated that this number will grow to over 160,000 procedures by the year 2012. Traditionally, lumbar spinal stenosis has been treated with a laminectomy.

Related Links:

Alphatec Spine
Helix Point



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.